Inhibition of Lapatinib-induced Kinome Reprogramming in ERBB2-positive Breast Cancer by Targeting BET Family Bromodomains

Therapeutics such as lapatinib that target ERBB2 often provide initial clinical benefit but resistance frequently develops. Adaptive responses leading to lapatinib resistance involve reprogramming of the kinome through reactivation of ERBB2/ERBB3 signaling and transcriptional upregulation and activa...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cell Rep
Prif Awduron: Stuhlmiller, Timothy J., Miller, Samantha M., Zawistowski, Jon S., Nakamura, Kazuhiro, Beltran, Adriana S., Duncan, James S., Angus, Steven P., Collins, Kyla A. L., Granger, Deborah A., Reuther, Rachel A., Graves, Lee M., Gomez, Shawn M., Kuan, Pei-Fen, Parker, Joel S., Chen, Xin, Sciaky, Noah, Carey, Lisa A., Earp, H. Shelton, Jin, Jian, Johnson, Gary L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4408261/
https://ncbi.nlm.nih.gov/pubmed/25865888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2015.03.037
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg